Corporate Knights ranks Toronto Hydro first among electricity transmission and distribution utilities in Canada
TORONTO, June 26, 2025 /CNW/ - Toronto Hydro has ranked first for corporate citizenship among electricity transmission and distribution utilities in Canada in Corporate Knights Magazine's annual ranking. Toronto Hydro also earned the sixth spot in the magazine's annual ranking of the Best 50 Corporate Citizens.
For more than 20 years, Corporate Knights Inc. has published one of the world's largest circulation magazines with a specific focus on the intersection of business and sustainability.
This year's ranking assessed 344 companies using a set of environmental, social and governance indicators. Each organization was evaluated against their industry peers using publicly available information.
Toronto Hydro's recognition reflects its strong performance in sustainability, including its commitment to reaching net-zero direct emissions (known as scope one) and significantly reducing indirect emissions (scope two) by 2040. This recognition also highlights Toronto Hydro's ongoing efforts to enhance grid reliability and foster a diverse and inclusive workplace.
To learn more about Toronto Hydro's environmental performance, please visit torontohydro.com/environment.
QUICK FACTS
This is the eighth time that Toronto Hydro has been recognized for its leadership in Environmental, Social and Governance, sustainability and climate adaptation by Corporate Knights Inc.'s Best 50 Corporate Citizens in Canada list
Toronto Hydro is one of only 12 electrical utilities in Canada to be designated as a Sustainable Electricity Leader™ by Electricity Canada, in recognition of its sustainability performance
Toronto Hydro operates an externally certified Environmental, Health and Safety Management System in accordance with the International Organization for Standardization's (ISO) 2015 Standard for Environmental Management Systems (ISO 14001:2015) and 2018 Standard for Occupational Health and Safety Management Systems (ISO 45001:2018)
Electric vehicles and plug-in hybrid electric vehicles account for 30 per cent of Toronto Hydro's fleet
Toronto Hydro achieved a 19 per cent reduction in building emissions in 2024 compared to 2019
QUOTE
"At Toronto Hydro, sustainability isn't just a goal, it's embedded in our purpose and values. Being recognized by Corporate Knights for the eighth time reflects our commitment to powering a cleaner, more resilient Toronto while supporting the city's journey to net-zero. We're proud to lead by example in building a sustainable energy future for all Torontonians."
- Jana Mosley, President and CEO, Toronto Hydro
ABOUT TORONTO HYDRO
Toronto Hydro is a holding company which wholly owns two subsidiaries:
Toronto Hydro-Electric System Limited (THESL) – distributes electricity; and
Toronto Hydro Energy Services Inc. – provides streetlighting and expressway lighting services in the city of Toronto
The principal business of Toronto Hydro and its subsidiaries is the distribution of electricity by THESL, which owns and operates the electricity distribution system for Canada's largest city. Recognized as a Sustainable Electricity Leader™ by Electricity Canada, it has approximately 796,000 customers located in the city of Toronto and distributes approximately 18 per cent of the electricity consumed in Ontario.
SOCIAL MEDIA ACCOUNTS
SOURCE Toronto Hydro Corporation
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
6 hours ago
- Cision Canada
Hisense Showcases AI Technology Strength with "AI YOUR LIFE" Message at FIFA Club World Cup 2025™
QINGDAO, China, June 30, 2025 /CNW/ -- Hisense, a leading brand in global consumer electronics and home appliances, is showcasing its AI leadership at the FIFA Club World Cup 2025™ with the bold pitch-side message "AI YOUR LIFE," reflecting the brand's vision of human-centric innovation through intelligent technology. As one of the earliest consumer tech brands to explore AI, Hisense is integrating intelligent features across its product portfolio. Today, at the core of Hisense's intelligent ecosystem is the Hi-View AI Engine X—its most powerful AI processor yet. Powered by deep neural networks, it learns and adapts like a human brain, optimizing picture and sound across all content, from fast-paced sports to cinematic films and immersive gaming. Driving the next generation of ULED AI TVs, Hi-View AI Engine X powers four key pillars: AI Picture for lifelike contrast, color, and motion; AI Sound for adaptive clarity and immersive acoustics; AI Scenario for automatic mode switching; and AI Energy for top performance with greater efficiency. Together, they create a more immersive, intelligent way to enjoy every match, goal, and moment on screen. Beyond the screen, Hisense expands smart connectivity in the home through ConnectLife. From AI-guided cooking to personalized laundry care, users enjoy seamless, scenario-based intelligence. The PureFlat Smart Series refrigerator, with its 21-inch screen, serves as a convenient hub to manage appliances with ease. For Hisense, whether it's screen or appliance, the essence is home — and the essence of home is love. Now enhanced by AI, that belief evolves—technology becomes more intuitive, responsive, and emotional. As global audiences celebrate football's finest moments, Hisense invites everyone to "Own the Moment" with intelligent products that understand, adapt, and inspire. About Hisense Hisense, founded in 1969, is a globally recognized leader in home appliances and consumer electronics with operations in over 160 countries, specializing in delivering high-quality multimedia products, home appliances, and intelligent IT solutions. According to Omdia, Hisense ranks No. 2 worldwide in total TV volume shipments (2022-2024) and No. 1 globally in the 100-inch and over TV segment (2023- Q12025). As the first official partner of the FIFA Club World Cup 2025™, Hisense is committed to global sports partnerships as a way to connect with audiences worldwide.
Cision Canada
7 hours ago
- Cision Canada
Piramal Pharma Solutions Breaks Ground on $90M Expansion Plan
Piramal Pharma Solutions is investing $90M to expand two of its U.S. facilities, adding commercial-scale manufacturing capabilities and significantly enhancing the capacity and efficiency of each site. Both facilities undergoing expansions are essential components of Piramal Pharma's integrated antibody-drug conjugate (ADC) offering, ADCelerate™, reflecting the company's commitment to delivering innovative solutions that align with patient needs. Piramal Pharma celebrated the groundbreaking of the expansion of its sterile injectables development and manufacturing facility on June 25, 2025. MUMBAI, India, June 30, 2025 /CNW/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), recently announced a $90M investment plan to expand two of its U.S. facilities, which are critical to its integrated offering. This ambitious investment underscores the company's commitment to industry leadership through continuous growth and innovation. The two sites involved in the expansion are: Riverview, Michigan: The Riverview site provides comprehensive drug substance development and manufacturing services, including specialized solutions for high potency APIs (HPAPIs). This facility is a vital element of ADCelerate™, supplying the payload-linkers essential to the overall safety, stability, and efficacy of ADC therapies. The expansion will add a commercial-scale suite specifically designed for the development and manufacturing of payload-linkers, which is expected to be operational by the end of 2025. Lexington, Kentucky: The Lexington site is Piramal Pharma's dedicated fill/finish facility, specializing in sterile compounding, liquid filling, and lyophilization for sterile injectable drug products. As a critical component of Piramal Pharma's integration, the site provides fill/finish services for all integrated programs, including ADCelerate™ projects. The expansion will add commercial-scale sterile injectable manufacturing capabilities with 24,000 additional square feet of manufacturing space, a new laboratory, and state-of-the-art machinery, including a new filling line, two commercial-size lyophilizers, a specialized capping machine, and an external vial washer. The expansion is expected to be completed by late 2027. Piramal Pharma recently broke ground on the expansion plan for its Lexington, Kentucky facility. To celebrate this important milestone and the future growth it signifies for the company, Piramal Pharma hosted a groundbreaking ceremony at the facility on June 25, 2025. This investment comes at a pivotal moment for the sterile injectables market, which is experiencing significant growth driven by increased medical necessity, broader regulatory approvals, and sizable advancements in scientific research and development. Additionally, the streamlined delivery systems associated with sterile injectables contribute to their efficacy and safety, making these solutions increasingly popular among both healthcare providers and patients. Similarly, ADC therapies are gaining substantial traction, fueled by ongoing innovation, wider regulatory acceptance, and robust evidence demonstrating their effectiveness. The growing prevalence of ADCs underscores the pressing need for expanded manufacturing and development capabilities to meet the evolving landscape of patient care. This investment positions Piramal Pharma to capitalize on these trends, ensuring the company can meet the rising demand for both sterile injectables and ADC therapies while enhancing its competitive edge in the market. Upon completion of the expansion in late 2027, the Lexington site will more than double its manufacturing capacity, increasing from 104 product batches per year (at peak utilization) to over 240 annual batches. "We prioritize patient, consumer, and customer centricity in all our operations, engaging with the populations we serve to better understand, anticipate, and address their needs. Our research has revealed that the sterile injectables market is projected to exceed $20B by 2028, underscoring the urgent need for us to enhance our offerings in this segment. We are confident that this strategic $90M investment will empower us to meet the demands of this market, reinforcing our position as a trusted global partner in biologic manufacturing. By enhancing the services we provide to our partners, we can reduce the burden of disease for more patients around the globe," said Nandini Piramal, Chairperson, Piramal Pharma. "As the market adjusts and preferences shift, we are committed to adapting to meet its current requirements," said Peter DeYoung, Chief Executive Officer, Piramal Global Pharma. "ADCs are rapidly emerging as one of the most effective classes of precision immunotherapy targeting certain cancers and tumors. As this class of drugs becomes more prevalent, we will adapt our services to accommodate this growing demand. By investing in the Lexington and Riverview facilities, we will enhance our integrated ADC offering, ADCelerate™, and increase our capacity to bring high-quality, innovative treatments to our clients and their patients worldwide." The Lexington facility expansion also represents an investment in the local community, creating 40 new full-time jobs that will enhance the local economy and strengthen Piramal Pharma's workforce. Piramal Pharma will continue to work alongside local partners, leveraging the region's strengths to remain at the forefront of innovation. Additionally, this investment aligns with the growing trend toward U.S. onshore manufacturing, reinforcing the company's dedication to domestic production in the U.S. and supply chain resilience. At the groundbreaking ceremony, Lexington Mayor Linda Gorton expressed her excitement about the project and the promising opportunities it presents for the city, stating, "Piramal's decision to expand its facility here in Lexington sends a message around the world that Lexington is a great place to do business. Lexington is home to one of the nation's best pharmacy programs – the University of Kentucky College of Pharmacy – and we are well on our way to becoming a leader in the pharmaceutical industry, as well." Others echoed Mayor Gorton's sentiment with equal enthusiasm, including Jim Stephanou, CEO of IPS-Integrated Project Services, who said, "IPS is a proud supporter of Piramal's growth over the past five years, providing fit-for-purpose solutions on transformative projects across India, the UK, Canada, and the U.S. Our longstanding relationship is built on trust and a relentless commitment to technical excellence. Nothing is more rewarding than seeing shovels in the ground, especially here in Lexington. This groundbreaking highlights our deep expertise in Aseptic Fill/Finish facilities, and our passion to help Piramal bring this advanced manufacturing facility to life to deliver critical therapies to patients around the world." Commerce Lexington President and CEO, Bob Quick, said, "We are proud to celebrate this milestone moment with Piramal and excited for its continued growth and success. Biotech is a key strategic target for Greater Lexington economic development professionals, and this expansion will further strengthen the region as a hub for biotech and life sciences. Piramal's investment highlights the advantages of the area as an exceptional place where innovative companies come to grow and thrive." Piramal Pharma Solutions' $90M investment in its U.S. facilities represents a significant advancement in its manufacturing capabilities and underscores its ongoing commitment to patient-centric care. This strategic move will enable Piramal Pharma to meet the evolving needs of the healthcare landscape, positioning the company at the forefront of the rapidly growing sterile injectables and ADC markets and ensuring a brighter future for patients and communities alike. About Piramal Pharma Solutions Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited. About Piramal Pharma Limited Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments. * Includes one facility via PPL's minority investment in Yapan Bio.
Cision Canada
3 days ago
- Cision Canada
RepTrak Previews Compass -- A Global Strategic Reputation Intelligence Platform that is More Than a Score
BOSTON, June 27, 2025 /CNW/ -- The RepTrak Company™, the global leader in reputation intelligence for over 20 years, unveils RepTrak Compass™, its most advanced and globally scalable platform to date. Launching this July, Compass empowers Chief Communications Officers and C-suite leaders to not just monitor stakeholder reputation, but to actively shape it with speed, precision, and confidence. More than a score, Compass is the only truly integrated global solution for reputation intelligence — combining RepTrak's world-class Global Advisory expertise with AI-enabled navigation. Designed for today's dynamic stakeholder environment, Compass enables leaders to shift from measuring reputation to actively shaping it. "Compass was engineered to deliver what today's executives need most — fast, reliable intelligence that drives action," says Chip Garate, Chief Product and Technology Officer at RepTrak. "Where do we stand with each stakeholder group? What reputational risks are emerging? Where should we act? Compass delivers not just data or a score — it delivers clarity, confidence, and direction." With two decades of reputation science and global benchmarking across 60+ countries, Compass is built on the most trusted foundation in the industry. RepTrak's expertise and experience in advising the world's largest global brands means there is nothing we haven't seen and everything we've learned is built into this platform. RepTrak would like to extend a special thank you to the members of its Customer Advisory Council, comprised of Fortune 500 companies, for their invaluable insights and partnership in shaping the development of Compass. Their input was instrumental in ensuring the platform meets the most critical and real-time needs of today's reputation leaders. Compass is not just a step forward, it's the future of reputation leadership. It unites insight and action across geographies, stakeholder groups, and leadership levels, helping today's teams lead with clarity and confidence. Compass Delivers Global Strategic Advantage Through: Multi-Stakeholder Tracking and Prioritization Continuous visibility into the perceptions of Employees, Policymakers, Media, Investors, Customers, and the Informed Public — locally and globally. Executive-Ready Reporting Tools Provide C-suite and Board leaders with clear, concise data visualizations and recommendations that drive decisions. Global Industry and Peer Benchmarking Position your reputation against global competitors, industry norms, and regulatory expectations with precision. Integrated Global Advisory Partnership Every Compass client gains a direct strategic advantage through RepTrak's Global Advisory team — a partner in transforming insight into action across all regions. AI-Powered Navigation Real-time, globally informed guidance that helps mitigate risks and build brand equity before issues escalate. Availability Compass will officially launch this July with a phased global rollout to RepTrak clients. Early feedback from select enterprise users reinforces Compass as a game-changing advancement, enabling organizations to not just monitor reputation, but to proactively manage it. RepTrak invites communications, corporate affairs, brand, and reputation leaders around the world to explore Compass — and see how it empowers them to lead reputation, not just report on it. To get a sneak peek of Compass and learn more, visit About The RepTrak Company The RepTrak Company is the world's premier provider of reputation data and insights, helping businesses harness reputation intelligence to secure competitive advantage. RepTrak's predictive insights enable subscribers to safeguard business value, optimize ROI, and amplify their positive societal impact. Combining advanced metrics with dedicated reputation advisors, RepTrak delivers actionable analyses that align business goals with stakeholder sentiment across global markets and diverse industries. Established in 2004, The RepTrak Company owns the world's largest reputation benchmarking database, gathering over 1 million company ratings per year used by CEOs, boards, and executives in more than 60 countries worldwide. For more information, please visit
